{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:49:59Z","timestamp":1791665399633,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002767","name":"China Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2024JK2115"],"award-info":[{"award-number":["2024JK2115"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171399"],"award-info":[{"award-number":["82171399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371413"],"award-info":[{"award-number":["82371413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571597"],"award-info":[{"award-number":["82571597"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.clineuro.2026.109660","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:08:26Z","timestamp":1791151706000},"page":"109660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Individualized Ofatumumab versus Fixed Low\u2010Dose Rituximab in MuSK\u2010Antibody\u2010Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study"],"prefix":"10.1016","volume":"272","author":[{"given":"Qian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-2544","authenticated-orcid":false,"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2026.109660_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102488","article-title":"MuSK antibodies, lessons learned from poly- and monoclonality","volume":"112","author":"Vergoossen","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clineuro.2026.109660_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.clineuro.2026.109660_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2026.109660_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1439899","article-title":"Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109660_bib5","doi-asserted-by":"crossref","first-page":"7219","DOI":"10.1038\/s41598-025-90937-w","article-title":"Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis","volume":"15","author":"Chayanopparat","year":"2025","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.clineuro.2026.109660_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clineuro.2026.109660_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.clineuro.2026.109660_bib8","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2026.109660_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1278250","article-title":"Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells","volume":"14","author":"Li","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2026.109660_bib10","article-title":"Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab","volume":"15","author":"Song","year":"2024","journal-title":"Front. Immunol."},{"issue":"1756-2856 (Print","key":"10.1016\/j.clineuro.2026.109660_bib11","article-title":"Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"19","author":"Zhou","year":"2026","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2026.109660_bib12","first-page":"721","article-title":"Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)","volume":"58","author":"Shi","year":"2025","journal-title":"Chin. J. Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.clineuro.2026.109660_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.clineuro.2026.109660_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nmd.2013.02.008","article-title":"Performance of individual items of the quantitative myasthenia gravis score","volume":"23","author":"Barnett","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.clineuro.2026.109660_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109660_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.clineuro.2026.109660_bib18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatol. (Oxf. )"},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/mus.27233","article-title":"Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody","volume":"63","author":"Zhou","year":"2021","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.clineuro.2026.109660_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/fampra\/cmae009","article-title":"The burden of recurrent respiratory tract infections in adult population: a population-based study in primary care","volume":"41","author":"Lapi","year":"2024","journal-title":"Fam. Pract."},{"key":"10.1016\/j.clineuro.2026.109660_bib21","article-title":"Efficacy and safety of low-dose rituximab in MuSK antibody-positive myasthenia gravis: a single-center retrospective study","volume":"17","author":"Yang","year":"2026","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cortes-Vicente","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109660_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2026.109660_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/NDT.S358851","article-title":"Efficacy and safety of low-dose rituximab in Anti-MuSK myasthenia gravis patients: a retrospective study","volume":"18","author":"Meng","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"7","key":"10.1016\/j.clineuro.2026.109660_bib25","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study","volume":"266","author":"Singh","year":"2019","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109660_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.clineuro.2026.109660_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2026.109660_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419871187","article-title":"Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis","volume":"12","author":"Choi","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109660_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.clineuro.2026.109660_bib30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int. Rep."},{"issue":"10","key":"10.1016\/j.clineuro.2026.109660_bib31","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1681\/ASN.2021040561","article-title":"Human or chimeric monoclonal Anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109660_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.coi.2005.03.001","article-title":"Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex","volume":"17","author":"Rickert","year":"2005","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib33","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.3390\/ijms18061249","article-title":"Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes","volume":"18","author":"Cataldi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/mus.27393","article-title":"Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >\/=65 years old","volume":"64","author":"Doughty","year":"2021","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.clineuro.2026.109660_bib35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"6","key":"10.1016\/j.clineuro.2026.109660_bib38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","article-title":"Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study","volume":"41","author":"Wade","year":"2021","journal-title":"Rheumatol. Int."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726003525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726003525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:07:55Z","timestamp":1791662875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846726003525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":38,"alternative-id":["S0303846726003525"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109660","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized Ofatumumab versus Fixed Low\u2010Dose Rituximab in MuSK\u2010Antibody\u2010Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109660"}}